Q32 BioQTTB
Market Cap: $591M
About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Employees: 41
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
39% more funds holding
Funds holding: 38 [Q1] → 53 (+15) [Q2]
15% more capital invested
Capital invested by funds: $125M [Q1] → $144M (+$18.2M) [Q2]
161.84% less ownership
Funds ownership: 229.13% [Q1] → 67.3% (-161.84%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wells Fargo Sarah Akers 100% 1-year accuracy 1 / 1 met price target | 94%upside $95 | Overweight Initiated | 11 Sept 2024 |